Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1970 1
1972 1
1973 1
1980 1
1982 2
1985 1
1987 2
1988 9
1989 2
1990 10
1991 14
1992 12
1993 18
1994 17
1995 20
1996 13
1997 15
1998 22
1999 26
2000 19
2001 30
2002 28
2003 43
2004 52
2005 53
2006 52
2007 72
2008 53
2009 43
2010 43
2011 45
2012 63
2013 112
2014 221
2015 253
2016 303
2017 307
2018 384
2019 396
2020 360
2021 435
2022 405
2023 425
2024 166

Text availability

Article attribute

Article type

Publication date

Search Results

4,156 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for france lu
Search for Francine Lu instead (1 results)
RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France.
Terroir M, Lamesa C, Krim M, Vija L, Texier JS, Cassou-Mounat T, Delord JP, Vallot D, Courbon F. Terroir M, et al. Pharmaceuticals (Basel). 2023 May 16;16(5):754. doi: 10.3390/ph16050754. Pharmaceuticals (Basel). 2023. PMID: 37242537 Free PMC article. Review.
Many malignant cells could be treated with [(177)Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. ...We review the literature on this subject and offer a clinical illustration of compassionate use in France as a p …
Many malignant cells could be treated with [(177)Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pa …
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.
Ladrière T, Faudemer J, Levigoureux E, Peyronnet D, Desmonts C, Vigne J. Ladrière T, et al. Pharmaceutics. 2023 Apr 13;15(4):1240. doi: 10.3390/pharmaceutics15041240. Pharmaceutics. 2023. PMID: 37111725 Free PMC article. Review.
Since the first market authorization in 2018 of [177Lu]Lu-DOTATATE (Lutathera) targeting somatostatin receptor type 2 in the treatment of gastroenteropancreatic neuroendocrine tumors, intensive research has led to transfer innovative (177)Lu containing pharmaceutica …
Since the first market authorization in 2018 of [177Lu]Lu-DOTATATE (Lutathera) targeting somatostatin receptor type 2 in the treatmen …
Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free article. Clinical Trial.
BACKGROUND AND OBJECTIVE: [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific membrane antigen (PSMA)-po …
BACKGROUND AND OBJECTIVE: [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617) plus the standard of care (SoC) significantly improve …
Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.
Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lähdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S. Stenman LK, et al. EBioMedicine. 2016 Nov;13:190-200. doi: 10.1016/j.ebiom.2016.10.036. Epub 2016 Oct 26. EBioMedicine. 2016. PMID: 27810310 Free PMC article. Clinical Trial.
For relative change in body fat mass, LU+B420 showed a-4.5% (-1.4kg, P=0.02, N=37) difference to the Placebo group, whereas LU (+0.3%, P=1.00, N=35) and B420 (-3.0%, P=0.28, N=24) alone had no effect (overall ANOVA P=0.095, Placebo N=35). ...DISCUSSION: This clinica …
For relative change in body fat mass, LU+B420 showed a-4.5% (-1.4kg, P=0.02, N=37) difference to the Placebo group, whereas LU …
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. Senan S, et al. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811519 Clinical Trial.
ISV Congress back to Europe.
Doolan DL, Lu S. Doolan DL, et al. Hum Vaccin Immunother. 2018;14(9):2101-2104. doi: 10.1080/21645515.2018.1518065. Hum Vaccin Immunother. 2018. PMID: 30285587 Free PMC article. No abstract available.
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD, Carmes L, Atis S, Parach A, Bertolet A, Jarlier M, Poty S, Garcia DS, Shin WG, Du Manoir S, Schuemann J, Tillement O, Lux F, Constanzo J, Pouget JP. Garcia-Prada CD, et al. J Nucl Med. 2023 Dec 1;64(12):1956-1964. doi: 10.2967/jnumed.123.265418. J Nucl Med. 2023. PMID: 37857502 Free PMC article.
Next, the therapeutic efficacy and toxicity of 5 MBq of [(177)Lu]Lu-DOTA-trastuzumab with Gd-NPs (3 administration regimens) were evaluated. ...Moreover, compared with [(177)Lu]Lu-DOTA-trastuzumab alone, the strongest therapeutic efficacy (tumor mass r …
Next, the therapeutic efficacy and toxicity of 5 MBq of [(177)Lu]Lu-DOTA-trastuzumab with Gd-NPs (3 administration regimens) w …
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours.
Plas P, Limana L, Carré D, Thiongane A, Raguin O, Mansi R, Meyer-Losic F, Lezmi S. Plas P, et al. Pharmaceuticals (Basel). 2022 Aug 30;15(9):1085. doi: 10.3390/ph15091085. Pharmaceuticals (Basel). 2022. PMID: 36145306 Free PMC article.
Histopathological and immunohistochemical examinations were performed at different timepoints. In the in vitro assays, [(177)Lu]Lu-satoreotide tetraxetan recognised twice as many SST(2) binding sites as [(177)Lu]Lu-DOTA-TATE. ...This was associated wit …
Histopathological and immunohistochemical examinations were performed at different timepoints. In the in vitro assays, [(177)Lu]Lu …
4,156 results